Researchers claim a combination of high sodium and low potassium is worse for heart health than either factor alone.
A new study linking sodium and potassium intake levels to cardiovascular disease (CVD) sheds new light on our understanding of CVD risk reduction. The study is published in the journal Archives of Internal Medicine.
Researchers from Harvard University, Emory University, and the Centers for Disease Control and Prevention examined data available from 12,267 subjects who participated in the Third National Health and Nutrition Examination Survey (NHANES III). Subjects participated in physical examinations and interviews for diet and lifestyle factors. All subjects were at least 20 years of age and had no history of CVD. Subjects participated in follow-up for an average of 14.8 years.
During the study, 36% of subjects died from CVD.
After adjusting for sex, race, body mass index, and other variables, higher sodium intake was associated with higher CVD mortality rates and higher potassium rates were associated with lower CVD morality rates.
But the combination of high sodium and low potassium created even greater CVD risk than either factor alone. The highest quartile of sodium-to-potassium ratio came with a 46% increased risk of CVD compared to the lowest quartile.
“High sodium levels induce increased blood pressure and hypertension by stiffening endothelial cells, thickening and narrowing resistance arteries, and blocking nitric oxide synthesis, whereas high potassium levels can counteract these effects by activating nitric oxide release,” wrote the study’s author. “The opposite biological effects of sodium and potassium may explain stronger associations of sodium-potassium ratio with CVD mortality than either sodium or potassium intake alone.”
The author noted that previous research on a link between the sodium-potassium ratio and CVD risk has been inconsistent, but this could be due to poorly designed studies.
“Public health recommendations should emphasize simultaneous reduction in sodium intake and increase in potassium intake,” concluded the author.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.